MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
26.37
+0.08
+0.30%
After Hours: 25.85 -0.52 -1.97% 17:00 03/26 EDT
OPEN
26.00
PREV CLOSE
26.29
HIGH
26.82
LOW
26.00
VOLUME
179.07K
TURNOVER
--
52 WEEK HIGH
52.24
52 WEEK LOW
15.50
MARKET CAP
487.14M
P/E (TTM)
1.354
1D
5D
1M
3M
1Y
5Y
1D
Top 10 undervalued small-cap stocks with high growth grades
Seeking Alpha · 16h ago
Weekly Report: what happened at RIGL last week (0316-0320)?
Weekly Report · 3d ago
Rigel’s New Olutasidenib Interaction Study Signals Long-Game Strategy for RIGL Investors
TipRanks · 6d ago
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
The Motley Fool · 03/16 22:56
Weekly Report: what happened at RIGL last week (0309-0313)?
Weekly Report · 03/16 10:24
Rigel Pharmaceuticals publishes corporate presentation on commercial product sales growth and development pipeline expansion
Reuters · 03/10 20:15
Rigel Pharmaceuticals: Growing Where It Matters
Seeking Alpha · 03/10 10:49
Weekly Report: what happened at RIGL last week (0302-0306)?
Weekly Report · 03/09 10:25
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.